Evidence map›Paper›PMID 20730056›Full record

Trial reportPloS one2010

Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial.

Sunil Sazawal, Usha Dhingra, Girish Hiremath, Archana Sarkar, Pratibha Dhingra, Arup Dutta, Priti Verma, Venugopal P Menon, Robert E Black

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 6 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01251783 phase3completednot on this map

Double Blind, Randomized, Controlled Clinical Trial for Evaluate The Efficiency and Safety of a Fiber System From Agave, With Prebiotic Action, Metlin® and Metlos®, Incorporated to an Infant Formula for Term Newborn Babies

TypeinterventionalSponsorNational Institute of Pediatrics, MexicoRan2010 to 2010Enrolled600ConditionsHealthy Term BabiesArmsInfant Formula, Exclusively breast milk, Metlin+metlos+Lactobacillus GG, Metlin + Lactobacillus GG, Metlos + lactobacillus GG
NCT02687503 nacompletednot on this mapstarted 2017, after this paper: background citation

Impact of Probiotic Use on Immune Cell Function in Children

TypeinterventionalSponsorUniversity of Wisconsin, MadisonRan2017 to 2019Enrolled23ConditionsRespiratory Tract InfectionsArmsProbiotic
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 6 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  4. Pooled it
  5. Probiotics for preventing acute otitis media in children.The Cochrane database of systematic reviews · 2019
    Pooled it
  6. Probiotics for preventing ventilator-associated pneumonia.The Cochrane database of systematic reviews · 2014
    Pooled it
  7. Trial
  8. Probiotics in addition to antibiotics for the treatment of acute tonsillitis: a randomized, placebo-controlled study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015
    Trial
  9. Trial
  10. Trial
  11. Efficacy of Pyloshot in combination with standard four-drug antimicrobial treatment forJGH open : an open access journal of gastroenterology and hepatology · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Gut Microbiota and Diarrhea: An Updated Review.Frontiers in cellular and infection microbiology · 2021
    Review
  17. Frontiers in nutrition · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sunil SazawalJohns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Usha Dhingra
Girish Hiremath
Archana Sarkar
Pratibha Dhingra
Arup Dutta
Priti Verma
Venugopal P Menon
Robert E Black
Annamalai University · INJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent reviews suggest common infectious diseases continue to be a major cause of death among preschool children in developing countries. Identification of feasible strategies to combat this disease burden is an important public health need. We evaluated the efficacy of adding prebiotic oligosaccharide and probiotic Bifidobacterium lactis HN019 to milk, in preventing diarrhea, respiratory infections and severe illnesses, in children aged 1-4 years as part of a four group study design, running two studies simultaneously. METHODS AND

findingsIn a community based double-masked, randomized controlled trial, children 1-3 years of age, willing to participate, were randomly allocated to receive either control milk (Co; n = 312) or the same milk fortified with 2.4 g/day of prebiotic oligosaccharide and 1.9x10(7) colony forming unit (c.f.u)/day of probiotic Bifidobacterium lactis HN019 (PP; n = 312). Children were followed up for 1 year providing data for 1-4 years. Biweekly household surveillance was conducted to gather information on compliance and morbidity. Both study groups were comparable at baseline; compliance to intervention was similar. Overall, there was no effect of prebiotic and probiotic on diarrhea (6% reduction, 95% Confidence Interval [CI]: -1 to 12%; p = 0.08). Incidence of dysentery episodes was reduced by 21% (95% CI: 0 to 38%; p = 0.05). Incidence of pneumonia was reduced by 24% (95% CI: 0 to 42%; p = 0.05) and severe acute lower respiratory infection (ALRI) by 35% (95% CI: 0 to 58%; p = 0.05). Compared to children in Co group, children in PP group had 16% (95% CI: 5 to 26%, p = 0.004) and 5% (95% CI: 0 to 10%; p = 0.05) reduction in days with severe illness and high fever respectively. CONCLUSIONS/SIGNIFICANCE: Milk can be a good medium for delivery of prebiotic and probiotic and resulted in significant reduction of dysentery, respiratory morbidity and febrile illness. Overall, impact of diarrhea was not significant. These findings need confirmation in other settings.

Indexed as

PrebioticsProbioticsUrban PopulationAnimalsBifidobacteriumChild, PreschoolDiarrheaDouble-Blind MethodFood, FortifiedHumansInfantMilkMorbidityOligosaccharidesRespiratory Tract InfectionsTimeOligosaccharidesPrebiotics

Identifiers

PMID20730056
PMCPMC2921405
OpenAlexW2017457530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.